CN102050864A - Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof - Google Patents
Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof Download PDFInfo
- Publication number
- CN102050864A CN102050864A CN 201010555974 CN201010555974A CN102050864A CN 102050864 A CN102050864 A CN 102050864A CN 201010555974 CN201010555974 CN 201010555974 CN 201010555974 A CN201010555974 A CN 201010555974A CN 102050864 A CN102050864 A CN 102050864A
- Authority
- CN
- China
- Prior art keywords
- sylvan life
- ginseng saponin
- life ginseng
- saponin
- wild ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a transplanted wild ginseng ginsenoside B as well as an extraction method and medical application thereof, belonging to the medical field. The extraction method comprises the following steps of: crushing a dry transplanted wild ginseng root, heating with ethanol for backflow and extraction, concentrating under reduced pressure, extracting to obtain an n-butyl alcohol part, then separating, purifying to obtain the transplanted wild ginseng ginsenoside B. The transplanted wild ginseng ginsenoside B is applied to preparing medicaments for treating myocardial ischemia, hemorrhagic shock, arrhythmia and reperfusion injury.
Description
Technical field
The present invention relates to sylvan life ginseng saponin(e B and extracting method thereof and its application in preparation treatment myocardial ischemia, ischemic shock, arrhythmia and reperfusion injury medicine.
Background technology
The wild ginseng of the Northeast is well-known, and not only domestic situation of selling well is also quite sold well in the world.Owing to cost an arm and a leg, a large amount of predatorinesses of people are excavated, and make the wild ginseng resource fewer and feweri, are on the verge of disappearance.Under the situation of supply-demand imbalance, the mid-80 is cultivated garden ginsent in a large number.The deforestation seed ginseng though alleviated the demand of market to genseng, owing to changed the forest environment of genseng growth, is added and is used chemical fertilizer, sprays insecticide etc., causes constituent of ginseng to change, and the efficacy of a drug weakens, and residual the exceeding standard of farming loses original medicinal function.China's genseng once found no sale in the international market, and price is kept falling, and in addition, the overdevelopment garden ginsent has also caused destruction to ecotope, causes forest resource decrease, severe water and soil erosion.After country implemented " Tian Bao engineering ", the genseng price began to go up.Under the prerequisite that effectively protects forest resources, cultivating the ginseng under forest similar to wild ginseng becomes the task of top priority.
Nineteen sixties, the Fu Song county, township of panax ginseng in jiljn took the lead in planting experimentally " sylvan life ginseng ", begin to set up the base one after another and cultivate " sylvan life ginseng " to state-run ginseng such as the eighties Jilin, Liaoning, Heilungkiang factory, ginseng factory of collective, up to the present, only China the Northeast " sylvan life ginseng " area is with regard to about more than 50 ten thousand mu, can provide sylvan life to join more than 2,000 kilogram every year to market, more than 500 kilogram of conversion dry product, the cultivation of sylvan life ginseng, plantation and popularization make the wild ginseng resource obtain historical recovery.
Sylvan life ginseng (Panax ginseng C.A.Meyer cv.Silvatica), claim also " sylvan life seed " that " seed goods " is that manual type is sowed the garden ginsent seed in remote, thickly forested mountains, seed germinates naturally, in wild environment self-sow, make goods through gathering again after the several years.New edition pharmacopeia in 2005, name be " sylvan life ginseng ", 2006, be revised as " ginseng under forest ".It is a kind of efficient complex ecological economic system pattern that genseng is cultivated in sylvan life, and the area of deforestation seed ginseng will be controlled and reduce to its development effectively, alleviates the contradiction between the forestry of high economic benefit ginseng planting's industry and high ecological benefits.This mode all has great importance for the development of Sustainable development that promotes the forest reserves and the production of ginseng industry.The fundamental research of sylvan life ginseng is still a blank at present, and along with die-offing of wild ginseng quantity, the plantation of sylvan life ginseng is increasingly extensive with application, and the research of carrying out this respect is imperative.
Summary of the invention
The invention provides sylvan life ginseng saponin(e B and extracting method and its pharmaceutical use.
White powder (CH
3OH), mp:180 ℃～182 ℃.The Liebermann-Burchard reaction is positive, and the Molish reaction is positive.10% sulphuric acid hydrolysis PC detects glucose.Be from the sylvan life ginseng, to separate the monomeric compound that obtains, so called after sylvan life ginseng saponin(e B.Chemical name is 3-O-β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl-11,12-epoxy-Da Ma-20S, 24S-epoxy-3 β, 12 β, the 25-triol (3-O-[β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl]-11,12-epoxy-dammar-20S, 24S-epoxy-3 β, 12 β, 25-triol).
The preparation method of sylvan life ginseng saponin(e B comprises the following steps: among the present invention
A, extraction: get exsiccant sylvan life ginseng root 1.4kg, pulverize, extract 3 times with 65%～85% alcohol heating reflux, be respectively 3h, 2h, 1h at every turn, filter united extraction liquid, be evaporated to relative density 1.12～1.15, use sherwood oil, trichloromethane, ethyl acetate, n-butanol extraction successively respectively, decompression and solvent recovery gets propyl carbinol part 100～120g to doing.
B, separation: with the propyl carbinol that obtains is that 200～300 purpose column chromatography silica gels carry out column chromatography for separation with specification partly, adopt the volume ratio trichloromethane: the eluent of methyl alcohol=8: 1～8 carries out wash-out, collect sylvan life ginseng saponin(e B part elutriant, reclaim solvent and get the thick product of sylvan life ginseng saponin(e B, yield 0.013～0.019%;
The purifying of c, sylvan life ginseng saponin(e B: separate the sylvan life that obtains and join saponin(e B crude product, also can adopt the recrystallizing methanol method to carry out purifying, can get the about 0.2g～0.3g of ginseng saponin(e B under the pure forest by carrying out column chromatography purification or preparative liquid chromatography purifying once more.
Do not see at present the extracting method of relevant sylvan life ginseng saponin(e B and the report of compound, this compound belongs to new compound, belongs to separate first to obtain; The pharmaceutical use that this compound is new belongs to first to be found.
The present invention can be used for preparation treatment coronary heart disease, myocardial ischemia, ischemic shock, medicines such as arrhythmia and reperfusion injury.Its oral or parenteral admin, all be safe, under oral situation, it can any conventionally form administration, as powder, granula, tablet, capsule, pill, solution, suspension, syrup, buccal tablets, sublingual lozenge etc.: when this medicine administered parenterally, can take any conventionally form, for example injection: as intravenous injection, ointment, suppository, percutaneous dosing, inhalation etc.
The medicine that the present invention prepares treatment coronary heart disease, myocardial ischemia, ischemic shock, arrhythmia and reperfusion injury is to be made of effective constituent monomer or the effective constituent vehicle with solid or liquid, the vehicle of solid used herein or liquid is well known in the art, lift several object lessons below, powder is the powder agent that takes orally, its vehicle has lactose, starch, paste essence, lime carbonate, synthetic or puritan filler aluminium, magnesium oxide, Magnesium Stearate, sodium bicarbonate, dry yeast etc.; The vehicle of solution has water, glycerine, 1,2-propylene glycol, simple syrup, ethanol, ethylene glycol, polyoxyethylene glycol, Sorbitol Powder etc.; The vehicle of ointment can use fatty oil, and hydrous wool, Vaseline, glycerine, honeybee is cured, wood is cured, white oil, resin, senior hydrophobizing agent or the hydrophilizing agent that is combined into such as cured.
Beneficial effect of the present invention is that new compound sylvan life ginseng saponin(e B can be used for preparation treatment coronary heart disease, myocardial ischemia, and ischemic shock, the medicine of arrhythmia and reperfusion injury has characteristics evident in efficacy.
The dosage of active substance can be according to the mode of taking, and patient's age and body weight and the degree that is in a bad way change with other similar factor, and oral dose is: 9.0～16.0mg/kg, and every day, secondary was taken: injection 7.0～9.0mg/kg, once a day.
Description of drawings
Fig. 1 is of the present invention
1The HNMR spectrogram;
Fig. 2 is of the present invention
13The CNMR spectrogram;
Fig. 3 is an ESI-MS spectrogram of the present invention.
Embodiment
Embodiment 1:
A, extraction: get exsiccant sylvan life ginseng root 1.4kg, pulverize, with concentration is that 65% (V/V) alcohol heating reflux extracts 3 times, be respectively 3h, 2h, 1h at every turn, filter united extraction liquid, be evaporated to relative density 1.12～1.15, use sherwood oil, trichloromethane, ethyl acetate, n-butanol extraction successively respectively, decompression and solvent recovery gets propyl carbinol part 110g to doing;
B, separation: with the propyl carbinol that obtains is that 200～300 purpose column chromatography silica gels carry out column chromatography for separation with specification partly, adopt trichloromethane: the eluent of methyl alcohol (V/V)=8: 1 carries out wash-out, collect sylvan life ginseng saponin(e B part elutriant, reclaim solvent and get the thick product of sylvan life ginseng saponin(e B, yield 0.019%;
The purifying of c, sylvan life ginseng saponin(e B: separate the sylvan life ginseng saponin(e B crude product that obtains and adopt recrystallization method to carry out purifying, get pure forest ginseng saponin(e B:0.3g down.
Identify: adopt method of spectroscopy to carry out structure and identify.
The ESI-MS spectrum of sylvan life ginseng saponin(e B provides: molecular weight is 799.4[M+1]
+Quasi-molecular ion peak gives m/z 637.3[M+H-glu]
+Fragment peak, and m/z 475.3[M+H-glu-glu]
+Fragment peak, in conjunction with
13CNMR,
1The HNMR spectrum determines that its molecular formula is C
42H
70O
14
1HNMR spectrum High-Field provide 8 methyl hydrogen signal: δ 1.381 (3H, s), 1.300 (3H, s), 1.235 (3H, s), 1.183 (3H, s), 1.075 (6H, s), 0.805 (3H, s), 0.777 (3H, s); The midfield provides 14 proton signals of two groups of glucose, comprising the anomeric proton signal δ 4.894 of two sugar (1H, d, J=8.0Hz), 5.355 (1H, d, J=7.5Hz) and other proton signals of glucose; According to the chemical shift in conjunction with end group carbon of the coupling constant of the anomeric proton signal of glucose, two glucose are beta comfiguration as can be known; (J=12.0 4.5Hz) is the H-3 signal to δ 3.232, does not provide the alkene hydrogen signal for 1H, dd; With 3-O-β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl-Da Ma-20S, 24S-epoxy-3 β, 12 β, 25-triol (J.P.liu, D.Lu, Y.Zhao, P.Y.Li and X.Li.A new semisynthetic ocotillol-type saponin and resuscitation of haemorrhagic shock[J] .Journal of asian natural products research, 2007,9 (2): 103-113.) relatively, former H-12 (δ 3.75) blackout, and a new signal (1H appears at δ 3.058, d, J=9.5Hz); (1H m) is the H-17 signal to δ 2.695;
1Give other proton signal in the HNMR spectrum.
13The CNMR spectrum provides 42 carbon signals altogether; Comprise two groups of glucose carbon signals, be respectively δ 105.075,83.367,77.935,71.586,78.289,62.817 and 106.00,77.083,78.289,71.623,78.153,62.698; δ 88.583 is the characteristic signal of genseng glycol saponins C-3 position; δ 56.098 is the characteristic signal of genseng glycol saponins C-5 position; With this compound
13CNMR data and 3-O-β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl-Da Ma-20S, 24S-epoxy-3 β, 12 β, the data of 25-triol are compared, the side chain cyclization part basically identical that shows the two promptly also contains the carbon signal of one group of furan nucleus in this structure.Rule (Toshinobu morita according to furans triterpenoid C-24 steric configuration, RyoJi kasai, Osamu Tanaka, et al.Saponins of Zu-Tziseng, Rhizomes of Panax Japonicus C.A.Meyer Var.major (Burk) C.Y.Wu, K.M.Feng, collected in Yunnan, China[J] .Chem.Pharm.Bull.1982,30 (12): 4341-4346.), the difference of 24R, 24S is
13The chemical shift difference of CNMR, promptly δ 85～86 is the 24R configuration, and δ 88～89 is the 24S configuration, and the C-24 chemical shift of this compound is 88.241, so judge that the C-24 steric configuration of this compound is the S configuration.Again according to rule (the Sei Ji fuJita of furans triterpenoid C-20 steric configuration, RyoJi kasai, Kazuhiro ohtani, et al.Dammarane glycosides from aerial part of Neoalsomitra Integrifoliola[J] .Phytochemistry, 1995,39 (3): 591-602.), the key distinction of 20R, 20S is C-21's
13CNMR chemical shift difference, promptly δ 19～20 is the 20R configuration, and δ 28～29 is the 20S configuration, and the C-21 chemical shift of this compound is δ 26.806, so judge that the C-20 steric configuration of this compound is the S configuration.
According to
1HNMR and
13The information that CNMR spectrum is provided belongs to the hydrocarbon nuclear magnetic data of this compound, the results are shown in Table 1.The hydrogen spectrum of sylvan life ginseng saponin(e B (
1HNMR spectrum), the carbon spectrum (
13CNMR spectrum) and mass spectrum (ESI-MS spectrum) see Fig. 1, Fig. 2 and Fig. 3 of accompanying drawing respectively.
The NMR data of table 1 sylvan life ginseng saponin(e B
Analytical results to sum up, identify that this compound is 3-O-β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl-11,12-epoxy-Da Ma-20S, 24S-epoxy-3 β, 12 β, the 25-triol (3-O-[β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl]-11,12-epoxy-dammar-20S, 24S-epoxy-3 β, 12 β, 25-triol).Through the Sciencefinder literature search, find no the report that closes this compound, be a new compound, called after sylvan life ginseng saponin(e B.
Embodiment 2:
A, extraction: get exsiccant sylvan life ginseng root 1.4kg, pulverize, with concentration is 75% ethanol (V/V) heating and refluxing extraction 3 times, be respectively 3h, 2h, 1h at every turn, filter united extraction liquid, be evaporated to relative density 1.12～1.15, use sherwood oil, trichloromethane, ethyl acetate, n-butanol extraction successively respectively, decompression and solvent recovery gets propyl carbinol part 120g to doing;
B, separation: with the propyl carbinol that obtains is that 200～300 purpose column chromatography silica gels carry out column chromatography for separation with specification partly, adopt trichloromethane: the eluent of methyl alcohol (V/V)=2: 1 carries out wash-out, collect sylvan life ginseng saponin(e B part elutriant, reclaim solvent and get the thick product of sylvan life ginseng saponin(e B, yield 0.013%;
The purifying of c, sylvan life ginseng saponin(e B: separate the sylvan life ginseng saponin(e B crude product that obtains and carry out purifying by column chromatography once more, get pure forest ginseng saponin(e B:0.20g down.
Embodiment 3:
A, extraction: get exsiccant sylvan life ginseng root 1.4kg, pulverize, with concentration is 85% ethanol (V/V) heating and refluxing extraction 3 times, be respectively 3h, 2h, 1h at every turn, filter united extraction liquid, be evaporated to relative density 1.12～1.15, use sherwood oil, trichloromethane, ethyl acetate, n-butanol extraction successively respectively, decompression and solvent recovery gets propyl carbinol part 100g to doing.
B, separation: with the propyl carbinol that obtains is that 200～300 purpose column chromatography silica gels carry out column chromatography for separation with specification partly, adopt trichloromethane: the eluent of methyl alcohol (V/V)=1: 1 carries out wash-out, collect sylvan life ginseng saponin(e B part elutriant, reclaim solvent and get the thick product of sylvan life ginseng saponin(e B, yield 0.016%;
The purifying of c, sylvan life ginseng saponin(e B: separate the sylvan life ginseng saponin(e B crude product that obtains and adopt preparative liquid chromatography to carry out purifying, get pure forest ginseng saponin(e B:0.23g down.
The present invention can further specify by following experimental example.
The influence of saponin(e B to hemorrhagic shock joined in experimental example one, sylvan life
One, experiment material and method
Material: 6 of domesticated dogs; Sylvan life ginseng saponin(e B is hereinafter to be referred as the PGGB:10mg/ml aqueous solution
Method: dog with Nembutal vein anesthetic (1ml), is lain on the back and is fixed on the operating table, separate tracheae, insert trachea cannula.Separate arteria carotis communis, connect RM-6000 four and lead physiograph, survey: BP (SBP/DBP); Separate right side bone artery, survey LVSP, LVEDP, ± dp/dt; Separate the right lateral thigh vein, be equipped with administrable.
Separate Right deviation side femoral artery, be equipped with arterial blood letting usefulness, connect cardiac diagnosis lead, survey ECG and calculate HR, xiphoid-process skin place connects force transducer with silk thread, surveys respiratory rate, after operation finishes, stablized 10 minutes, and write down every normal index, store in the blood bottle to filling 0.1% heparin-saline through the femoral artery bloodletting then, making the artery average pressure drop is that shock is (after bloodletting to 40mmHg, BP sharply descends, and can make the artery mean pressure maintain 40mmHg with in the defeated object that reverses of blood).Stablized 20 minutes, the artery mean pressure does not rise, and presses the 10mg/kgb administration, and observe 120 minutes every indexs and change, after the record administration 1,3,5,10,20,30,45,60,90,120 minutes.Venous blood collection, centrifugal, get serum, measure LPO (Ba Mushi improved method) and SOD.
Two, experimental result
1, to the influence of mean arterial blood pressure (MBP)
Sylvan life ginseng saponin(e B (PGGB) small dose group 20 ', 30 ' MBP after administration significantly raises, and compares with the saline control group, and notable difference (p＜0.05) is arranged.The rising percentage of 5 '～45 ' MBP is compared for two groups apparently higher than the saline control group, significant difference (p＜0.05, p＜0.01, p＜0.001).
The heavy dose of group of PGGB 5 '～120 ' MBP and rising percentage after administration have the highly significant meaning all apparently higher than saline control group (p＜0.05, p＜0.01, p＜0.001).
Dopamine HCL group 5 '～20 ' MBP after administration obviously raises, and the rising percentage of 5 '～30 ' MBP is compared with the salt solution group variant significantly (p＜0.05, p＜0.01) apparently higher than the saline control group.The results are shown in Table 1-1.
Table .1-1 PGGB is to the influence of MBP (Kpa)
Continuous table 1-1
Continuous table .1-1
*P＜0.05,
*P＜0.01,
* *Compare with the 0.9%NaCl control group p＜0.001.
2, the influence of right+dp/dt
The PGGB small dose group after administration 10 '～45 ' and 90 ', 120 '+dp/dt obviously increases the significant difference of comparing with the saline control group (p＜0.05, p＜0.01).The rising percentage of 30 '～120 '+dp/dt is significantly higher than the saline control group, compares that there were significant differences (p＜0.05, p＜0.01) for two groups.
The heavy dose of group of PGGB is 30 '～120 '+dp/dt and all significantly increases of rising percentage after administration, have compared highly significant meaning (p＜0.05, p＜0.01) with the saline control group.
The Dopamine HCL group is 5 '～45 '+dp/dt and all significantly increases of rising percentage after administration, compare significant difference (p＜0.05, p＜0.01, p＜0.001) with the saline control group.The results are shown in Table 1-2.
Table 1-2 PGGB is right+influence of dp/dt (Kpa/s)
Continuous table 1-2
Continuous table 1-2
Continuous table 1-2
Continuous table 1-2
P＜0.05,
*P＜0.01,
* *Compare with the 0.9%NaCl control group p＜0.001.
3, the influence of right-dp/dt
The rising percentage of PGGB small dose group 45 '-dp/dt after administration is apparently higher than the saline control group, the significant difference (p＜0.05) of comparing with the saline control group.
The heavy dose of group of PGGB 60 '-dp/dt after administration obviously raises, and the rising percentage of 10 '～60 '-dp/dt is compared (p＜0.05, p＜0.01) for two groups apparently higher than the saline control group.
Dopamine HCL group 5 ', 10 '-dp/dt after administration compares significant difference (p＜0.01) apparently higher than the saline control group with the saline control group.The rising percentage of 5 '～20 '-dp/dt is compared significant difference (p＜0.05, p＜0.01) apparently higher than the saline control group with the saline control group.The results are shown in Table 1-3.
Table 1-3 PGGB is right-influence of dp/dt (Kpa/s)
Continuous table 1-3
Continuous table 1-3
Continuous table 1-3
Continuous table 1-3
*P＜0.05,
*Compare with the 0.9%NaCl control group p＜0.01.
Heart rate and respiratory rate: compare no significant difference when each time point is with shock after administration.
The result shows: sylvan life ginseng saponin(e B (PPGB) has the anti-hemorrhagic shock effect.
Experiment two, sylvan life ginseng saponin(e B are to the hemodynamic influence of normal anesthetized dog (n=6)
One, experiment material and method
Material: 6 of domesticated dogs, body weight 13kg～15kg body weight, each 3 of male and female, sylvan life ginseng saponin(e B:10mg/ml solution;
Method: method is with experiment one, so slightly.
Two, result
1, to the influence of lipid peroxide (LPO)
Little, the heavy dose of group of PGGB content of 120 ' LPO after administration is starkly lower than the saline control group, two groups of comparing differences remarkable (p＜0.05).
The content of Dopamine HCL group 120 ' LPO after administration is starkly lower than the saline control group, two groups of comparing differences remarkable (p＜0.05).The results are shown in Table 2-1.
Table 2-1 PGGB is to the influence of LPO (A/ml)
Compare with the 0.9%NaCl control group p＜0.05.
2, to the influence of superoxide-dismutase (SOD)
The content of PGGB small dose group 120 ' SOD after administration and percentage and saline control group relatively do not have significant difference.
The content of the heavy dose of group of PGGB 120 ' SOD after administration and rising percentage be apparently higher than the saline control group, and two groups of comparing differences are (p＜0.05, p＜0.01) significantly.
The content of Dopamine HCL group 120 ' SOD after administration and rising percentage are apparently higher than the saline control group, and two groups of comparing differences remarkable (p＜0.01) the results are shown in Table 2-2.
Table 2-2 PGGB is to the influence of SOD (U/l)
*P＜0.05,
*Compare with the NaCl control group p＜0.01.
The result shows: sylvan life ginseng saponin(e B can significantly reduce LPO and improve SOD content, and anti-radical action is arranged.
The embodiment one of preparation medicament:
Sylvan life ginseng saponin(e B 35g, 1,2-propylene glycol 10000ml packs into after the mixing 1000 and pacifies in the bottle, and every 10ml contains sylvan life ginseng saponin(e B35mg.
The embodiment two of preparation medicament:
Sylvan life ginseng saponin(e B20.0g, medical starch 480g, the two thorough mixing, encapsulated, make 1000 capsules, every heavy 0.5g contains sylvan life ginseng saponin(e B20mg.
Claims (5)
- One kind as shown in the formula sylvan life ginseng saponin(e B,Its chemical name is: 3-O-β-D-glucopyranosyl-(1-2)-and β-D-glucopyranosyl-11,12-epoxy-Da Ma-20S, 24S-epoxy-3 β, 12 β, 25-triol.
- 2. the preparation method of sylvan life ginseng saponin(e B according to claim 1 is characterized in that, comprises the following steps:A, extraction: get exsiccant sylvan life ginseng root 1.4kg, pulverize, extract 3 times with 65%～85% alcohol heating reflux, be respectively 3h, 2h, 1h at every turn, filter united extraction liquid, be evaporated to relative density 1.12～1.15, use sherwood oil, trichloromethane, ethyl acetate, n-butanol extraction successively respectively, decompression and solvent recovery gets propyl carbinol part 100～120g to doing;B, separation: with the propyl carbinol that obtains is that 200～300 purpose column chromatography silica gels carry out column chromatography for separation with specification partly, adopt the volume ratio trichloromethane: the eluent of methyl alcohol=8: 1～8 carries out wash-out, collect sylvan life ginseng saponin(e B part elutriant, reclaim solvent and get the thick product of sylvan life ginseng saponin(e B, yield 0.013～0.019%;The purifying of c, sylvan life ginseng saponin(e B: separate the sylvan life ginseng saponin(e B crude product that obtains by carrying out column chromatography purification, preparative liquid chromatography purifying once more, or adopt the recrystallizing methanol method to carry out purifying, can get and join the about 0.2g～0.3g of saponin(e B pure forest under.
- 3. the preparation method of sylvan life ginseng saponin(e B according to claim 2 is characterized in that: ethanol can use methyl alcohol, water to replace.
- 4. the preparation method of sylvan life ginseng saponin(e B according to claim 2, it is characterized in that: the separator column chromatographic stuffing also comprises gac, diatomite, macroporous adsorbent resin or aluminum oxide.
- 5. the application of sylvan life ginseng saponin(e B as claimed in claim 1 in preparation treatment coronary heart disease, myocardial ischemia, ischemic shock, arrhythmia and reperfusion injury medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010555974 CN102050864B (en) | 2010-11-24 | 2010-11-24 | Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010555974 CN102050864B (en) | 2010-11-24 | 2010-11-24 | Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102050864A true CN102050864A (en) | 2011-05-11 |
| CN102050864B CN102050864B (en) | 2013-01-02 |
Family
ID=43955708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010555974 Expired - Fee Related CN102050864B (en) | 2010-11-24 | 2010-11-24 | Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102050864B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106805243A (en) * | 2017-02-28 | 2017-06-09 | 吉林省清评科技有限公司 | A kind of high-valued method of comprehensive utilization of Ginseng under Forest |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518540A (en) * | 2009-03-27 | 2009-09-02 | 吉林华康药业股份有限公司 | Medical composition |
-
2010
- 2010-11-24 CN CN 201010555974 patent/CN102050864B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518540A (en) * | 2009-03-27 | 2009-09-02 | 吉林华康药业股份有限公司 | Medical composition |
Non-Patent Citations (2)
| Title |
|---|
| 《Journal of Asian Natural Products Research》 20070331 J.P.liu,et al. A new semisynthetic ocotillol-type saponin and resuscitation of haemorrhagic shock 第106-107页 5 第9卷, 第2期 * |
| 《医药卫生科技辑》 20081115 钟方丽 林下参化学成分及其生物活性的研究 第二章2.5.1.1中的化合物22,第二章2.3,第五章实验部分5.3.2.4 1-5 , * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106805243A (en) * | 2017-02-28 | 2017-06-09 | 吉林省清评科技有限公司 | A kind of high-valued method of comprehensive utilization of Ginseng under Forest |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102050864B (en) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103040882B (en) | Passiflora edulis sims stem-leaf extract as well as pharmaceutical composition and antidepressant action of extract | |
| CN104910240A (en) | Bougainvillea glabra triterpenoid saponin, hpyerglycemic drugs with triterpenoid saponin as active component and preparation method and application thereof | |
| CN113789214A (en) | Compound ganoderma lucidum spore oil for improving cancer-induced fatigue and preparation method and application thereof | |
| CN103349671A (en) | Resveratrol and spirulina composition and preparations and preparation method thereof | |
| CN103006769A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102875615B (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
| CN102614276A (en) | Dahurian rose fruit leaf general flavone extract, and extracting method and medical application thereof | |
| CN103360452B (en) | The Synthesis and applications of Muskmelon Base tetracyclic triterpene cucurbitane compound | |
| CN102050864B (en) | Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof | |
| CN104693262B (en) | Da Ma-20S, 25S-epoxy-3 β, 12 β, 26-triols and extracting method thereof and medicinal usage | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN102250197B (en) | Preparation method and application of total steroidal saponin extracts of dwarf lilyturf roots | |
| CN101948498B (en) | Pseudo-ginsenoside G2, extraction method and drug application thereof | |
| CN101411711B (en) | Composition containing alisol A and alisol A 24-acetic ester and use | |
| CN109303785B (en) | Application of lobetyolin analog compound in preparation of medicine for treating arrhythmia | |
| CN101099754A (en) | Preparation method and application for pedunculoside II | |
| CN104257756B (en) | The application in preparing hypoglycemic medicine of a kind of Cortex Mori fatty oil | |
| CN1068790C (en) | Medicinal composition containing total saponin extracted from stem and leaves of American ginseng | |
| CN1488355A (en) | Cough-relieving chinese medicine formulation of total glycoside of mango leaf | |
| CN101863945B (en) | American ginseng saponin F6 as well as extraction method and medical application thereof | |
| CN101928320B (en) | American ginseng ginsenoside F5ab and extraction method and medicinal application thereof | |
| CN105418722B (en) | A kind of entitled Sasanguasaponin C4And C5Pentacyclic triterpenoid preparation method | |
| CN116554254B (en) | Compound with sedative and insomnia relieving effects and application thereof | |
| JPH0481570B2 (en) | ||
| CN102125574B (en) | Medicinal composition for suppressing tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130102 Termination date: 20181124 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |